

may be associated with a variety of neuropsychiatric and motor syndromes. In addition, loss-of-function mutations in *TAHP1* are known to cause a variety of dystonia syndromes. Therefore, it is believed that brain calcinosis in this family is related to the deletion of *SLC20A2*, while the *TAHP1* deletion likely contributes to the early onset dystonia phenotype.

CONFLICTS OF INTEREST:

None.

ABSTRACT A4

Pathologic substrate, risk factors, and functional impact of delusions and hallucinations in neuropathologically diagnosed Alzheimer's disease

D. G. Munoz, W. Qian, T. A. Schweizer, C.E. Fischer

Keenan Research Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON

doi:10.1017/cjn.2015.370

Utilizing the National Alzheimer's Coordinating Center database we analyzed 728 patients with Alzheimer's disease (AD), neuropathologically confirmed based on the CERAD criteria, comparing those ($n = 271$) that at any moment in their evolution suffered delusions or hallucinations (P+) versus those ($n = 457$) that did not (P-). There was no difference in AD lesion load. P+ subjects had a higher prevalence of subcortical arteriosclerotic leukoencephalopathy (SAL) and, as expected, higher Lewy body stage. Hypertension was more common in P+ patients and diabetes in subjects with both delusions and hallucinations. P+ patients tended to quit smoking later in life. The functional associations diverged: patients with delusions only had better CDR, MMSE and FAQ than P-patients, whereas the opposite was true for patients with hallucinations, whether isolated or associated with delusions. In contrast, an overlapping sample of 890 subjects from the same database with a clinical diagnosis of AD and available neuropathological exam showed greater AD load in the P+ group, a result we interpret as due to clinical misdiagnosis, since the P- group was enriched in subjects with a Braak stage I and II. We conclude that SAL is, along with Lewy bodies, a substrate for psychotic symptoms in AD, and that vascular risk factors are likely to contribute to the development of this condition.

CONFLICTS OF INTEREST:

None.

ABSTRACT A5

Compared to normals, the cerebral expression of multiple inflammatory markers is reduced in Alzheimer's disease and Diffuse Lewy body disease

AC Lamport, J Warford, AS Easton

Department of Pathology, Dalhousie University, Halifax, NS

doi:10.1017/cjn.2015.371

The role of inflammation in the development of dementia is a controversial topic. However, inflammatory biomarkers could

be used to differentiate different subtypes of dementia, and monitor responses to therapy. Here we describe the results of a multi-plexed ELISA study using Bio-Plex Pro™ premixed 40-plex human cytokine kits to obtain an overview of inflammatory biomarker expression in the left frontal pole frozen at autopsy in pathologically verified cases of Alzheimer degeneration (Braak stage ≤ 3), AD (Braak stage ≥ 4), AD-DLBD (Braak stage ≤ 3), 'pure' DLBD (without AD pathology) and normal controls.

Compared to normals, significant reductions were observed in levels of Interleukin (IL)-6, Tumor Necrosis Factor, IL-1 β , and 5 CXCL (-2, -6, -11, -13, -16) and 4 CCL (-7, -15, -23, -26) chemokines in all cases. These reductions occurred in a stepwise fashion, with highest levels in cases of AD, followed by AD-DLBD, DLBD and Alzheimer degeneration. This suggests that inflammatory biomarkers reduce in the transition to AD, and undergo further profound reductions in cases of mixed AD-DLBD and particularly in cases of 'pure' DLBD. These results challenge the notion that dementia is characterized by increased brain inflammation, and suggest that biomarker reductions could be used to signal the onset of Alzheimer's disease, while sustained biomarkers during therapy could reflect neuroprotection.

CONFLICTS OF INTEREST:

None.

ABSTRACT A6

Understanding the role of surfen, a proteoglycan antagonist, in mouse models of multiple sclerosis: Applications for the development of novel therapeutics

J Warford, AC Lamport, DW Hoskin, AS Easton

Department of Pathology, Dalhousie University, Halifax, NS

doi:10.1017/cjn.2015.372

Connective tissue components such as proteoglycans are known inhibitors of remyelination in mouse models of demyelination and are found at the border of active demyelinating lesions in multiple sclerosis. Surfen (bis 2-methyl, 4-amino, 6-quinolyl amide) is a small molecule antagonist that preferentially binds heparan sulfate and related proteoglycans. We have previously reported that surfen reduces T cell proliferation *in vivo* and *in vitro*. Here we extend this work by characterizing surfen in mouse models of chronic neuroinflammation (experimental autoimmune encephalomyelitis; EAE) and demyelination (lysolecithin).

Female adult C57Bl/6 mice were immunized with myelin oligodendrocyte glycoprotein emulsified in a 1:1 ratio with complete Freund's adjuvant. Mice were scored daily and received either surfen (5mg/kg, i.p) or vehicle (DMSO, i.p.) every second day following the onset of clinical symptoms. In a separate cohort, lysolecithin was injected bilaterally into the corpus callosum of adult C57Bl/6 mice to induce demyelination.

Relative to vehicle treatment (0.1 % DMSO), stereotactic administration of surfen (100 μ M) 48 hours following lysolecithin increased total lesion area seven days post-injection with concomitant increases in glial and macrophage activity. By contrast, surfen (5 mg/kg, i.p.) ameliorated EAE clinical severity compared to vehicle controls. Taken together, these results signify that while peripheral proteoglycan antagonism by